Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$54.66

0.74 (1.37%)

, DAL

Delta Air Lines

$39.98

0.62 (1.58%)

07:35
10/04/16
10/04
07:35
10/04/16
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Monday in Bristol Myers Squibb (BMY), Delta (DAL), Merck (MRK), Newmont (NEM), Macys (M), Southwest Airlines (LUV), Himax Technologies (HIMX), SunTrust Banks (STI), Tempur Pedic (TPX), and GrubHub (GRUB).

BMY

Bristol-Myers

$54.66

0.74 (1.37%)

DAL

Delta Air Lines

$39.98

0.62 (1.58%)

MRK

Merck

$62.52

0.11 (0.18%)

NEM

Newmont Mining

$38.10

-1.19 (-3.03%)

M

Macy's

$36.28

-0.77 (-2.08%)

LUV

Southwest

$39.74

0.85 (2.19%)

HIMX

Himax

$8.67

0.08 (0.93%)

STI

SunTrust

$43.77

-0.03 (-0.07%)

TPX

Tempur Sealy

$54.30

-2.44 (-4.30%)

GRUB

GrubHub

$42.68

-0.31 (-0.72%)

  • 07

    Oct

  • 09

    Oct

  • 21

    Oct

  • 25

    Oct

  • 27

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

  • 17

    Nov

BMY Bristol-Myers
$54.66

0.74 (1.37%)

09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
DAL Delta Air Lines
$39.98

0.62 (1.58%)

07/14/16
RAJA
07/14/16
NO CHANGE
RAJA
Outperform
Delta Air Lines Q3 passenger unit revenue to pressure shares, says Raymond James
Raymond James analyst Savanthi Syth said Delta's Q2 came in slightly ahead of consensus but shares will likely be pressured on the Q3 passenger unit revenue outlook. The analyst said delta moderated Q4 capacity growth with winter cuts in the US-UK market, which should be viewed as a positive. Syth rates Delta an Outperform.
07/15/16
EVER
07/15/16
DOWNGRADE
EVER
Hold
Delta Air Lines downgraded to Hold from Buy at Evercore ISI
Evercore ISI analyst Duane Pfennigwerth downgraded Delta Air Lines to Hold with a $50 price target. The analyst said Delta's Q2 earnings were ahead but preliminary unit revenue guidance of down 4-6% implies no sequential improvement at midpoint despite 1 % point slower capacity growth. Pfennigwerth said revenue trends during the peak summer demand period are weaker and he would like to see evidence that corporate revenue trends have stabilized before becoming constructive on shares.
08/24/16
08/24/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lockheed Martin (LMT) reinstated with a Neutral at Goldman. 2. Five Below (FIVE) initiated with a Neutral at BTIG. 3. AMC Entertainment (AMC) and Cinemark (CNK) were initiated with a Buy at Loop Capital while the firm initiated Regal Entertainment (RGC) with a Hold. 4. Delta Air Lines (DAL) initiated with an In-Line at Imperial Capital. 5. LINE Corp. (LN) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, Reference Link
08/24/16
IMPC
08/24/16
INITIATION
Target $41
IMPC
In-Line
Delta Air Lines initiated with an In-Line at Imperial Capital
Imperial Capital analyst Michael Derchin initiated Delta Air Lines with an In-Line and $41 price target citing the potential impact on UK business travel from Brexit and deteriorating economic, social and terrorism problems in Europe.
MRK Merck
$62.52

0.11 (0.18%)

10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
08/19/16
UBSW
08/19/16
NO CHANGE
Target $70
UBSW
Buy
Merck price target raised to $70 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Merck (MRK) to $70 from $62 as he updated his model to account for a more favorable Keytruda opportunity following the failed CheckMate-026 trial at Bristol-Myers (BMY). The analyst also feels investors do not give enough credit to Merck's Januvia franchise or the potential for growth opportunity from the pipeline. Goodman reiterated his Buy rating on Merck shares.
09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
NEM Newmont Mining
$38.10

-1.19 (-3.03%)

05/11/16
GSCO
05/11/16
UPGRADE
Target $36
GSCO
Buy
Newmont Mining upgraded to Buy from Neutral at Goldman
Goldman analysts led by Andrew Quail upgraded Newmont Mining to Buy and raised his price target to $36 from $23.30. The analyst said Merian organic growth is now less than 6 months away and there is a possible Indonesia asset sale on the horizon. Quail believes Newmont is well positioned to outperform given his revised gold price deck that was lifted by 10-15% over the next three years, and for 2017, raised the average to $1,150/oz from $1,000/oz.
08/09/16
MSCO
08/09/16
INITIATION
Target $41
MSCO
Equal Weight
Newmont Mining initiated with an Equal Weight at Morgan Stanley
Target $41.
08/02/16
SBSH
08/02/16
INITIATION
Target $51
SBSH
Buy
Newmont Mining initiated with a Buy at Citi
Citi analyst Alexander Hacking started Newmont Mining with a Buy rating and $51 price target.
06/02/16
JEFF
06/02/16
DOWNGRADE
Target $33
JEFF
Hold
Newmont Mining downgraded to Hold from Buy at Jefferies
Jefferies analyst Christopher LaFemina downgraded Newmont Mining to Hold citing valuation, near-term gold price risk, potential U.S. interest rate increase headwinds and a lack of positive catalysts. The analyst lowered his price target for the shares to $33 from $38.
M Macy's
$36.28

-0.77 (-2.08%)

09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/16
GUGG
09/30/16
INITIATION
Target $45
GUGG
Buy
Macy's initiated with a Buy at Guggenheim
Guggenheim analyst Robert Drbul initiated Macy's with a Buy and a $45 price target saying shares offer a compelling risk reward ratio due to the company's healthy balance sheet, 4.2% dividend yield, and strong free cash flow.
09/28/16
FBCO
09/28/16
DOWNGRADE
Target $40
FBCO
Neutral
Macy's downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Michael Exstein downgraded Macy's (M) to Neutral saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. The analyst recommends swapping into Dillard's (DDS), which he upgraded this morning to Outperform. Exstein remains Underweight the Department Store space and keeps a $40 price target for shares of Macy's.
09/14/16
09/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Macy's (M) upgraded to Buy from Neutral at Citi with analyst Paul Lejuez saying an attractive free cash flow and dividend yield makes the risk/reward attractive at current levels. 2. Fifth Third (FITB) upgraded to Buy from Neutral at Compass Point. 3. F5 Networks (FFIV) upgraded to Outperform from Perform at Oppenheimer with analyst Ittai Kidron saying the company has several potential drivers that could drive year-over-year product revenue growth back into positive territory in fiscal 2017. 4. Las Vegas Sands (LVS) upgraded to Buy from Hold at Argus with analyst John Staszak saying that Macau gambling is shifting towards the non-VIP market, where he believes that Las Vegas Sands is well-positioned. 5. DeVry (DV) upgraded to Outperform from Market Perform at Barrington with analyst Alexander Paris saying management's near-term goal is stabilizing revenue at DeVry University growing enrollment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LUV Southwest
$39.74

0.85 (2.19%)

09/09/16
IMPC
09/09/16
INITIATION
Target $46
IMPC
Outperform
Southwest initiated with an Outperform at Imperial Capital
Imperial Capital analyst Michael Derchin started Southwest Airlines with an Outperform rating and $46 price target. Concerned that the company's cost gap will erode over time are overblown, Derchin tells investors in a research note. He believes Southwest warrants a premium valuation to the big three airlines since it can maintain a "meaningful cost and margin advantage because of its low cost business model."
07/27/16
JPMS
07/27/16
DOWNGRADE
Target $34
JPMS
Neutral
Southwest downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jamie Baker downgraded Southwest Airlines to Neutral saying the company continues to resist industry efforts aimed at improving revenue, like bag fees and fare increases. The analyst also sees labor uncertainty in 2017 from all three unions. He cut his price target for the shares to $34 from $52.50.
07/27/16
JPMS
07/27/16
UPGRADE
Target $78.5
JPMS
Overweight
Alaska Air upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jamie Baker upgraded Alaska Air Group (ALK) to Overweight saying the shares at current levels are "simply too cheap to ignore." The analyst highlights the company's "exemplary capital stewardship" and labor cost control in recent years. He raised his price target for the shares to $78.50 from $72.50. Baker this morning also downgraded Southwest Airlines (LUV) to Neutral.
07/27/16
07/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Hold from Buy at Canaccord, to Hold from Buy at Axiom, and to Hold from Buy at Cantor. 2. Southwest (LUV) downgraded to Neutral from Overweight at JPMorgan with analyst Jamie Baker saying the company continues to resist industry efforts aimed at improving revenue, like bag fees and fare increases. 3. Globus Medical (GMED) downgraded to Market Perform from Outperform at Wells Fargo, to Market Perform from Outperform at Leerink, and to Hold from Buy at Canaccord. 4. Linear Technology (LLTC) downgraded to Equal Weight from Overweight at Morgan Stanley. 5. Analog Devices (ADI) downgraded to Neutral from Buy at Citi with analyst Christopher Danely saying he views the stock as fairly valued at current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HIMX Himax
$8.67

0.08 (0.93%)

09/02/16
NOMU
09/02/16
NO CHANGE
Target $12
NOMU
Buy
Himax price target raised to $12 on better pricing at Nomura
Nomura analyst Donnie Teng noted that Himax has been able to raise its prices for its liquid crystal on silicon, or LCOS, and wafer level optics, or WLO, for a major augmented reality device recently, which he believes could help the company reach the higher end of its Q3 sales guidance. Teng raised his price target on Himax shares to $12 from $9.70, adding that the company plans to try to provide more cost effective LCOS and WLO products for a possible consumer AR device in 2018, which lead to higher demand. Nomura keeps a Buy rating on the stock.
09/29/16
FBCO
09/29/16
NO CHANGE
FBCO
Outperform
Himax long-term story intact, says Credit Suisse
Credit Suisse analyst Jerry Su lowered Himax's LCOS/WLO shipment assumptions for Q4-1H 2017 on slower new platform adoption following supply chain checks. Su said the 2018 AR device ramp is on track and believes Himax's long-term story on consumer AR glass and 3D sensing for smartphone remains intact, since the capacity ramp up remains on schedule. The analyst said the potential launch of consumer AR glass and 3D sensing for smartphone should boost Himax's earnings in 2018 and reiterates his Outperform rating and $14 price target.
09/26/16
NOMU
09/26/16
DOWNGRADE
NOMU
Neutral
Himax downgraded to Neutral from Buy at Nomura
09/28/16
ROTH
09/28/16
INITIATION
Target $10
ROTH
Buy
Himax initiated with a Buy at Roth Capital
Roth Capital analyst Suji Desilva initiated Himax with a Buy and a $10 price target. Desilva believes newer HIMX products can participate in growth of IoT device categories such as augmented reality and virtual reality head-mounted devices.
STI SunTrust
$43.77

-0.03 (-0.07%)

08/16/16
08/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Hain Celestial (HAIN) downgraded to Equal Weight from Overweight at Barclays, to Neutral from Buy at SunTrust, to Underweight from Neutral at Piper Jaffray, and to Underweight from Neutral at Atlantic Equities. 2. JPMorgan (JPM), SunTrust (STI), and Regions Financial (RF) downgraded to Market Perform from Outperform at Bernstein. 3. Performance Sports Group (PSG) downgraded to Neutral from Outperform at Wedbush with analyst James Hardiman saying the delay in the filing of the company's 10-K could cause it to default. 4. Ocean Rig UDW (ORIG) downgraded to Hold from Buy at Deutsche Bank with analyst Mike Urban saying the company's restructuring is likely unfavorable for existing equity holders. 5. Alarm.com (ALRM) downgraded to Market Perform from Outperform at Raymond James with the firm citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/16
BERN
08/16/16
DOWNGRADE
BERN
Market Perform
SunTrust downgraded based on valuation at Bernstein
As noted earlier, Bernstein downgraded SunTrust to Market Perform from Outperform. Analyst John McDonald downgraded the stock based on valuation. Additionally, the analyst says that banks will be hurt by an eventual downturn in credit metrics, while expectations of interest rate increases have diminished. Target remains $43.
07/25/16
07/25/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deere (DE) downgraded to Underweight from Neutral at Piper Jaffray with analyst Brett Wong citing expectations that the current agriculture downturn is going to persist in 2017 for a fourth consecutive year. 2. Whirlpool (WHR) downgraded to Market Perform from Strong Buy at Raymond James with analyst Sam Darkatsh saying risk/reward is no longer skewed positively given increasingly more difficult comps, a seasonally heavier promotional environment, and higher cost inflation for 2017. 3. SunTrust (STI) downgraded to Buy from Conviction Buy at Goldman with analyst Ryan Nash citing headwinds from net margin pressure and potential elevated expenses in the second half of 2016. 4. Tableau (DATA) downgraded to Hold from Buy at Deutsche Bank analyst Karl Keirstead saying he's incrementally concerned about price discounting and competition after speaking to the company's partners and customers. 5. Sabra Health Care (SBRA) downgraded to Underperform from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/16
BERN
08/16/16
DOWNGRADE
BERN
Market Perform
SunTrust downgraded to Market Perform from Outperform at Bernstein
TPX Tempur Sealy
$54.30

-2.44 (-4.30%)

09/28/16
LBOW
09/28/16
DOWNGRADE
LBOW
Neutral
Tempur Sealy downgraded to Neutral from Buy at Longbow
09/29/16
UBSW
09/29/16
INITIATION
Target $20
UBSW
Sell
Select Comfort initiated with a Sell at UBS
UBS analyst Michael Lasser started Select Comfort with a Sell rating and $20 price target. The analyst highlights as risks increasing competition and the company's reliance on existing customers. He recommends a "guarded" view of the mattress sector saying online-only players will grab "meaningful share" over the near-term. Lasser this morning also initiated shares of Tempur Sealy (TPX) with a Neutral rating.
09/29/16
UBSW
09/29/16
INITIATION
Target $60
UBSW
Neutral
Tempur Sealy initiated with a Neutral at UBS
UBS analyst Michael Lasser started Tempur Sealy with a Neutral rating and $60 price target. The analyst views the stock's risk/reward is "fairly even."
09/28/16
09/28/16
DOWNGRADE

Neutral
Tempur Sealy downgraded folloiwng guidance reduction at Longbow
As previously reported, Longbow downgraded Tempur Sealy to Neutral from Buy. Analyst Mark Rupe said Tempur Sealy surprised investors by pre-announcing negative Q3 sales have missed expectations and that sales and EBITDA guidance for 2016 would be lower, following one of its better performance in its history during Q2. Rupe believes shares will be range bound until demand trends improve and believes investors will take a wait-and-see approach in the interim.
GRUB GrubHub
$42.68

-0.31 (-0.72%)

10/04/16
STFL
10/04/16
DOWNGRADE
STFL
Hold
GrubHub downgraded to Hold from Buy at Stifel
Stifel analyst John Egbert downgraded GrubHub to Hold on valuation.
08/16/16
JEFF
08/16/16
INITIATION
Target $43
JEFF
Hold
GrubHub initiated with a Hold at Jefferies
Jefferies analyst David Reynolds started GrubHub with a Hold rating and $43 price target. The analyst views the company's U.S. market opportunity as less attractive than the U.K. He feels GrubHub has a complex business with "little transparency."
08/16/16
08/16/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. IBM (IBM) initiated with a Perform at Oppenheimer. 2. GrubHub (GRUB) initiated with a Hold at Jefferies. 3. Broadwind Energy (BWEN) initiated with an Outperform at Cowen. 4. TPI Composites (TPIC) initiated with an Overweight at JPMorgan, with an Outperform at Cowen, with a Buy at Canaccord, with an Overweight at Morgan Stanley, and with an Outperform at Raymond James. 5. Tableau (DATA) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/16
ADAM
09/27/16
NO CHANGE
Target $48
ADAM
Buy
GrubHub price target raised to $48 from $42 at Canaccord
Canaccord analyst Michael Graham believes sentiment on GrubHub has improved over the past several months, as evidenced in the upward move in shares since the company's Q2 report, and he thinks the competition has "yet to put a major dent in Grubhub's 3x audience lead over the next largest player." The analyst, who contends that the online market for take-out food in the U.S. remains "large and underpenetrated," raised his price target on GrubHub shares to $48 from $42 and keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

CELG

Celgene

$117.63

-1.24 (-1.04%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.